Company profile
PROTALIX BIOTHERAPEUTICS, INC.
AMEX:PLXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEGUNIGALSIDASE ALFA | phase3 | — | 6 | completed, withdrawn |
| TALIGLUCERASE ALFA | phase2 | — | 8 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (16)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05745727 | phase1 | completed | 2023-03-23 | 2024-08-26 | Protalix | A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels |
| NCT07280156 | phase2 | recruiting | 2025-12-22 | 2027-12-01 | Protalix | A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) |
| NCT01093859 | — | completed | 2010-03-01 | 2010-05-01 | Protalix | An Exploratory Phase 1 Microdose Study of PRX-105 |
| NCT02107846 | phase2 | completed | 2014-04-01 | 2015-12-01 | Protalix | An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 |
| NCT01678898 | phase1_2 | completed | 2012-10-01 | 2016-03-06 | Protalix | Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients |
FDA applications (0)
No records yet.